Publications
144
Citations
1,394
Est. group size
~12
Recurring co-author estimate
Active years
36
Publishing since 1991
Ralph Salloum is a pediatric neuro-oncology researcher focused on brain tumors in children, including medulloblastoma, atypical teratoid rhabdoid tumor, and diffuse hemispheric glioma. His work centers on multi-institutional clinical studies that evaluate treatment approaches (chemotherapy, radiation-sparing strategies) and their outcomes, as well as emerging tools like radiomics (using medical imaging data with computational methods) to help predict patient prognosis. Students interested in clinical trials, cancer treatment outcomes research, and imaging-based prognostic tools in pediatric oncology may find this work relevant.
Publication output has fluctuated over the past decade but remained fairly steady in recent years, averaging about 14 publications annually over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Cumulative dose of chemotherapy and survival outcomes in children with average-risk medulloblastoma treated on Children’s Oncology Group study ACNS0331
Neuro-Oncology · 2026
- Response Assessment in Pediatric Neuro-Oncology Symposium, Pediatric Society of Neuro-Oncology proceedings: Current status and future initiatives
Neuro-Oncology Pediatrics · 2026
- A multi-institutional report of children with atypical teratoid rhabdoid tumor treated with intensive multimodal therapy
Neuro-Oncology Practice · 2026
- Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Clinical Cancer Research · 2026
- Group 4 Medulloblastomas of Early Childhood Treated With High‐Dose Chemotherapy‐ and Craniospinal Irradiation‐Sparing Approach
Pediatric Blood & Cancer · 2026
- Sonic Hedgehog signaling pathway: overview and treatment considerations in brain tumors
Elsevier eBooks · 2026
- Supplementary Table S3 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
2026
- Supplementary Table S2 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
2026
- Supplementary Table S1 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
2026
- Data from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
2026
- Supplementary Table S4 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
2026
- Supplementary Figure S1 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
2026
- Supplementary Figure S2 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
2026
- Supplementary Table S5 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
2026
- Salvage therapies for first relapse of SHH medulloblastoma in early childhood
Neuro-Oncology · 2025
- Neuro-Oncology×45
- Figshare×13
- Pediatric Blood & Cancer×5
- Frontiers in Oncology×5
- Acta Neuropathologica Communications×4
- Scott Coven
Medicine · Indiana University
- Maryam Fouladi
Medicine · The Ohio State University
- Jonathan L. Finlay
Medicine · The Ohio State University
- Margot Lazow
Medicine · The Ohio State University
- Daniel R. Boué
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile